Archive for July 19th, 2010|Daily archive page


In BUSINESS OF STEM CELLS on July 19, 2010 at 2:44 pm

ReNeuron presents new data showing how its stem cells work to repair brain damage. 12/07/10

Guildford, UK, 12 July 2010: ReNeuron Group plc (LSE: RENE.L) today announces important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. The results of these studies will be presented in two posters1 at the UK National Stem Cell Network Annual Scientific Conference, taking place on 12 – 14 July, 2010 at the University of Nottingham, East Midlands Conference Centre, Nottingham, UK.

Image of stroke in the brain

In one series of studies, the angiogenic potential of the CTX stem cell line was tested, both in vitro and in rodent models of stroke damage. Angiogenesis is a multiple-step process whereby new blood vessels develop from pre-existing vasculature, potentially contributing to the functional recovery of the brain from damage such as that caused by ischaemic stroke. The results of these studies showed that the CTX cells express several trophic and pro-angiogenic factors in culture and also induce endothelial cell markers associated with blood vessel formation in the host at both 72 hours and 7 days post-implantation of the cells into the brain. Taken together, these results suggest that the CTX cells may play a role in promoting the functional recovery of stroke patients through up-regulation of angiogenesis in the region of ischaemic brain damage.

In a series of further studies, the CTX cells were seen to inhibit T cell activation. This immunosuppressive activity was in part attributed to the up-regulation of the ligand CD274, a regulator of T cell function. T cells are a type of white blood cell associated with the mediation of immune responses in the body. These results suggest that the CTX cells may act to suppress the inflammatory response associated with brain damage, thereby aiding the natural healing processes in the brain. This anti-inflammatory characteristic opens up a number of exciting new potential applications for the CTX cell line as a cell-based therapy for certain inflammatory diseases both within and beyond the brain.

ReNeuron recently announced the commencement of a UK Phase I clinical trial of its lead ReN001 stem cell therapy for disabled stroke patients. The ReN001 therapy represents the initial therapeutic application of the Company’s CTX stem cell line. Due in part to the anti-inflammatory properties of the CTX cells, patients in this clinical trial will not require immunosuppressive drug treatments alongside their cell therapy.

via ReNeuron –.

New approach of screening drugs that encourage stem cells to repair damaged tissue

In STEM CELLS IN THE NEWS on July 19, 2010 at 2:42 pm

New approach of screening drugs that encourage stem cells to repair damaged tissue

12. July 2010 06:13

Professor Fiona Watt will today (12 July) give the Anne McLaren Memorial Lecture at the UK National Stem Cell Network annual science meeting and will detail a new approach to screening for drugs that target stem cells. To begin with, this is being developed for adult skin stem cells, giving hope for new drugs to promote wound healing and aid the use of stem cells to, for example, treat severe burns. This technique can also be applied to a wide range of stem cells, opening up the possibilities for harnessing stem cells in regenerative medicine.

Professor Watt said “We are very interested in developing regenerative medicine as a way to heal our bodies when they can’t heal themselves – when the damage from an injury or disease is too severe, for example. For this type of approach to be successful it is important to have powerful ways of identifying the processes that stimulate stem cells to renew themselves or mature into the cells that are needed for healing. When we know what these processes are, we can use that knowledge to develop new treatments…

via New approach of screening drugs that encourage stem cells to repair damaged tissue.

Worldwide Medical Conference Draws over 30 Countries, 150 Top Scientists to Indianapolis, Indiana

In STEM CELLS IN THE NEWS on July 19, 2010 at 2:39 pm

Worldwide Medical Conference Draws over 30 Countries, 150 Top Scientists to Indianapolis, Indiana

The International Federation of Adipose Therapeutics and Science (IFATS) is holding their 2007 world medical and research conference in Indianapolis, Indiana, October 18-20. The conference will present advancements in research of Adipose derived stem cells This will be the last IFATS conference to be held in the United States in the near future, as the conference moves to France next year and South Korea in 2009.

Multidisciplinary investigators from over 30 countries will attend the three-day conference, hosted by Keith L. March, MD, PhD, current IFATS president, Professor of Medicine, Physiology, and Biomedical Engineering, Indiana University School of Medicine.

This is the only organization that focuses on the understanding and treatment of disease by probing into the characteristics of adipose tissue and its rich repository of stem cells. This meeting will be more exciting than ever before, with the field of adipose stem cells having demonstrated a truly remarkable growth in interest over the last year. This is based on a progressive recognition of the host of possibilities for addressing diseases that affect very many people, including those with heart disease, problems with circulation to the legs, stroke, neurological disorders, diabetes, obesity, hemophilia, autoimmune diseases, kidney disease, bone and joint problems, and others.

More than 150 researchers from over 30 countries will join with representatives from more than 15 companies that are actively working in the area of adipose stem cells. Keynote lectures from scientists who have made truly seminal contributions in the translational science of other important types of adult stem cells will greatly enrich the 2007 conference. Dr. Anthony Atala (leader in the field of amniotic-fluid derived stem cells). Dr. Hal Broxmeyer (discover of umbilical cord-blood derived stem cells), and Dr. Katarina LeBlanc (leader in the field of bone-marrow derived mesenchymal stem cells) will lecture in their respective disciplines. Biosketches of each of these speakers is available on the IFATS website: http://www.ifats.org. A number of new clinical trials using or planning the use of adipose stem cells in patients will be discussed by the investigators.

via Worldwide Medical Conference Draws over 30 Countries, 150 Top Scientists to Indianapolis, Indiana.

%d bloggers like this: